Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

    ... given in combination with low-dose cytarabine (LDAC) and decitabine can help control the disease in patients with AML or MDS. The ... to stop them from growing and repairing themselves. Decitabine is designed to damage the DNA of cells, which may cause cancer cells ...

    Clinical Trial last updated 04/29/2016 - 12:17pm.

  2. Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

    ... leukemia or myelodysplastic syndromes respond to decitabine . This study will contribute to the efforts to find effective and ... Associated Drug(s):  Decitabine Phase:  ...

    Clinical Trial last updated 04/29/2016 - 12:30pm.

  3. Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

    ... study is to learn if the combination of vosaroxin and decitabine can help to control AML or MDS. The safety of these drugs will ... Associated Drug(s):  Decitabine Phase:  ...

    Clinical Trial last updated 04/29/2016 - 11:49am.

  4. Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS

    ... Associated Drug(s):  Decitabine Phase:  ... Escalation Oral investigational product and approved IV decitabine Other Names: E7727 oral decitabine IV decitabine Drug: ASTX727 ...

    Clinical Trial last updated 04/27/2016 - 2:05pm.

  5. MDS Drug Therapy

    ... and high-risk patients with all sub-types of MDS Decitabine (Dacogen®) for both low- and high-risk patients with all ... Decitabine (Dacogen®) Decitabine ...

    Topic section last updated 03/10/2016 - 11:26pm.

  6. New therapeutics for myelodysplastic syndromes

    ... the azanucleosides, azacitidine (Vidazaâ) and decitabine (Dacogenâ).  Although these agents represent a significant ... the MDS clone:   The azanucleosides (azacitidine and decitabine) remain the best treatment option for many higher-risk MDS ...

    Research Review last updated 05/02/2016 - 9:28am.

  7. More is better: Combination therapies for myelodysplastic syndromes

    ... for MDS: lenalidomide , azacitidine , and decitabine .  Although these agents can be effective in the treatment of ... an epigenetic approach, where one combines azacitidine or decitabine (the class of drugs known as hypomethylating agents) with a class of ...

    Research Review last updated 05/02/2016 - 9:14am.

  8. Options for MDS patients beyond HMAs

    ... or after a period of response. HMAs, azacytidine and decitabine , were approved for International Prognostic Scoring System ... mutant proteins, IDH2; and SGI-110, a combination between decitabine and and deoxyguanine, with promising responses. For now, however, ...

    Research Review last updated 05/02/2016 - 9:09am.

  9. Recent developments in myelodysplastic syndromes

    ... between the years 2004 – 2006 ( azacitidine , decitabine , and lenalidomide ), none of these are curative.  In ... have consistently predicted response to azacitidine or decitabine.  -There are several novel agents and combinations of agents that ...

    Research Review last updated 05/02/2016 - 9:16am.

  10. Pathogenesis of MDS: An overview of molecular and non-molecular aspects of the disease

    ... for MDS: lenalidomide , azacitidine , and decitabine .  Although these agents can be effective in the treatment of ... responses to hypomethylating agents, such as azacitidine and decitabine. Splicing factor genes are mutated in about 50% of MDS patients ...

    Research Review last updated 05/02/2016 - 9:14am.